Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
Relmada Therapeutics (NASDAQ:RLMD), a clinical-stage biotechnology company focused on oncology and central nervous system therapies, will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 PM ET to discuss Q2 2025 financial results and business updates.
The conference call will be accessible via US dial-in (1-877-407-0792) and International dial-in (1-201-689-8263) with conference code 13754263. A webcast replay will be available in the Investors section of Relmada's website.
Relmada Therapeutics (NASDAQ:RLMD), un'azienda biotecnologica in fase clinica specializzata in terapie oncologiche e per il sistema nervoso centrale, terrà una conference call e una webcast giovedì 7 agosto 2025 alle 16:30 ET per discutere i risultati finanziari del secondo trimestre 2025 e gli aggiornamenti aziendali.
La conference call sarà accessibile tramite numero statunitense (1-877-407-0792) e numero internazionale (1-201-689-8263) con codice conferenza 13754263. La registrazione della webcast sarà disponibile nella sezione Investitori del sito web di Relmada.
Relmada Therapeutics (NASDAQ:RLMD), una empresa biotecnológica en etapa clínica enfocada en terapias oncológicas y del sistema nervioso central, realizará una llamada conferencia y una transmisión en vivo el jueves 7 de agosto de 2025 a las 4:30 PM ET para discutir los resultados financieros del segundo trimestre de 2025 y actualizaciones comerciales.
La llamada conferencia será accesible mediante marcación desde EE. UU. (1-877-407-0792) y marcación internacional (1-201-689-8263) con código de conferencia 13754263. La repetición de la transmisión estará disponible en la sección de Inversores del sitio web de Relmada.
Relmada Therapeutics (NASDAQ:RLMD)는 종양학 및 중추신경계 치료제에 중점을 둔 임상 단계 생명공학 회사로, 2025년 8월 7일 목요일 오후 4시 30분(동부시간)에 2025년 2분기 재무 결과 및 사업 업데이트를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 개최합니다.
컨퍼런스 콜은 미국 내 전화 접속(1-877-407-0792) 및 국제 전화 접속(1-201-689-8263)을 통해 회의 코드 13754263으로 참여할 수 있습니다. 웹캐스트 재방송은 Relmada 웹사이트의 투자자 섹션에서 제공됩니다.
Relmada Therapeutics (NASDAQ:RLMD), une société biotechnologique en phase clinique spécialisée dans les thérapies oncologiques et du système nerveux central, organisera une conférence téléphonique et une webdiffusion le jeudi 7 août 2025 à 16h30 ET pour discuter des résultats financiers du deuxième trimestre 2025 et des mises à jour commerciales.
La conférence téléphonique sera accessible via un numéro d'appel américain (1-877-407-0792) et un numéro d'appel international (1-201-689-8263) avec le code de conférence 13754263. La rediffusion de la webdiffusion sera disponible dans la section Investisseurs du site web de Relmada.
Relmada Therapeutics (NASDAQ:RLMD), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf Onkologie und Therapien des zentralen Nervensystems, wird am Donnerstag, den 7. August 2025, um 16:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten, um die Finanzergebnisse für das zweite Quartal 2025 sowie Geschäftsupdates zu besprechen.
Die Telefonkonferenz ist über eine US-Einwahlnummer (1-877-407-0792) und eine internationale Einwahlnummer (1-201-689-8263) mit dem Konferenzcode 13754263 zugänglich. Eine Wiederholung des Webcasts wird im Investor-Bereich der Relmada-Website verfügbar sein.
- None.
- None.
CORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress.
Conference Call and Webcast Information:
- Date: Thursday, August 7, 2025 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Conference: 13754263
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
When will Relmada Therapeutics (RLMD) report Q2 2025 earnings?
How can investors access Relmada's Q2 2025 earnings call?
What is Relmada Therapeutics' main business focus?
Where can investors find the replay of Relmada's Q2 2025 earnings call?
